,,ii  #aaeth ,,congress  #ast ,session  
,s4 #ajdi  ,,in ,,the ,,senate ,,of     
,,the ,,united ,,states  ,may #d1       
#bjag,ms4 ,hassan 7for herself and ,mr4 
,young7 introduced the following bill2  
which was read twice and referred to the
 ,committee on ,health1 ,education1     
,labor1 and ,pensions  ,a ,,bill  ,to   
allow the ,secretary of ,health and     
,human ,services to require that risk   
evaluation and mitigation strategies for
 certain drugs include communication    
plans that provide information about    
drug formulations or properties         
described in the drug labeling4  #a4    
,short title ,this ,act may be cited as 
the ,opioid ,addiction ,risk            
,transparency ,act4  #b4 ,,rems         
communication plans ,section            
#eje-a7;e77#c7 of the ,federal ,food1   
,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4
 #cee-a7;e77#c77 is amended--  7#a7 in  
subparagraph 7,b71 by striking 2 or2    
7#b7 in subparagraph 7,c71 by striking  
the period and inserting 2 or2 and  7#c7

 by adding at the end the following3    
7,d7 disseminating information to health
 care providers about the meaning of    
terms related to drug formulations or   
properties that are described in the    
drug labeling1 including information    
about the limitations or patient care   
implications of such formulations or    
properties1 and how such formulations or
 properties may be related to serious   
adverse drug events associated with use 
of the drug4  4